Synopsys, Inc. (SNPS) Tops Q3 EPS by 3c, Posts Q4 Gudiance and Raises FY11
Tweet
Share
E-mailGet Alerts SNPS Hot Sheet
Price: $413.21 +0.22%
Revenue Growth %: +40.2%
Financial Fact:
Upfront license: 79.65M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Revenue Growth %: +40.2%
Financial Fact:
Upfront license: 79.65M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Synopsys, Inc. (NASDAQ: SNPS) reported Q3 EPS of $0.46, $0.03 better than the analyst estimate of $0.43. Revenue for the quarter came in at $386.8 million versus the consensus estimate of $382.44 million.
Synopsys, Inc. sees Q4 2011 EPS of $0.44-$0.46, versus the consensus of $0.43. Synopsys, Inc. sees Q4 2011 revenue of $386-$392 million, versus the consensus of $383 million.
Synopsys, Inc. sees FY2011 EPS of $1.79-$1.81, versus the consensus of $1.75. Synopsys, Inc. sees FY2011 revenue of $1.53-$1.54 billion, versus the consensus of $1.52 billion.
Synopsys, Inc. sees Q4 2011 EPS of $0.44-$0.46, versus the consensus of $0.43. Synopsys, Inc. sees Q4 2011 revenue of $386-$392 million, versus the consensus of $383 million.
Synopsys, Inc. sees FY2011 EPS of $1.79-$1.81, versus the consensus of $1.75. Synopsys, Inc. sees FY2011 revenue of $1.53-$1.54 billion, versus the consensus of $1.52 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- Cellebrite DI Ltd. (CLBT) Tops Q2 EPS by 4c ; Offers Guidance
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
